March 2, 2021
Agreement focused on advancing Mitokinin’s PINK1 activator program for the potential treatment of Parkinson’s disease
February 7, 2020
Mitokinin CSO Nicholas Hertz, PhD, will be presenting an overview of the Company’s PINK1 program…
January 12, 2020
Mitokinin joined 300 delegates from the biopharma and venture industries and 35 peer companies at the 3rd annual Sachs Neuroscience Investor Forum…
October 15, 2019
Mitokinin today announced that The Michael J. Fox Foundation has awarded the Company a $300,000 grant to advance…
October 1, 2019
Mitokinin, a late-preclinical stage biotechnology company developing PINK1-targeted therapies for…
June 15, 2019
Copyright © 2021 Mitokinin. All rights reserved.
Website designed and developed by RainCastle Communications, Inc.